A non-human hepadnaviral adjuvant for hepatitis C virus-based genetic vaccines
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Swedish Research Council (K2012-99X-22017-01-3)
- Swedish Cancer Society
- Stockholm County Council
- VINNOVA
- Swedish Society of Medicine
- Goljes Memorial Fund
- Åke Wiberg Foundation
- Ruth and Richard Juhlin Foundation
- Magnus Bergwalls Foundation
- Karolinska Institutet/Södertörn University
- Karolinska Institutet
- ChronTech Pharma AB
This publication has 55 references indexed in Scilit:
- Therapeutic DNA Vaccination Using In Vivo Electroporation Followed by Standard of Care Therapy in Patients With Genotype 1 Chronic Hepatitis CMolecular Therapy, 2013
- A Heterologous Prime/Boost Vaccination Strategy Enhances the Immunogenicity of Therapeutic Vaccines for Hepatitis C VirusThe Journal of Infectious Diseases, 2013
- Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in ManScience Translational Medicine, 2012
- A Poxvirus Vaccine Is Safe, Induces T-Cell Responses, and Decreases Viral Load in Patients With Chronic Hepatitis CGastroenterology, 2011
- High Cleavage Efficiency of a 2A Peptide Derived from Porcine Teschovirus-1 in Human Cell Lines, Zebrafish and MicePLOS ONE, 2011
- Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis CVaccine, 2009
- Interaction of the Hepatitis B Core Antigen and the Innate Immune SystemThe Journal of Immunology, 2009
- Cleavage of the IPS-1/Cardif/MAVS/VISA does not inhibit T cell-mediated elimination of hepatitis C virus non-structural 3/4A-expressing hepatocytesGut, 2008
- Advantages to the use of rodent hepadnavirus core proteins as vaccine platformsVaccine, 2007
- Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide–based retroviral vectorNature Biotechnology, 2004